Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001193125-23-066791
Filing Date
2023-03-10
Accepted
2023-03-10 08:00:55
Documents
13
Period of Report
2023-03-09
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K/A d342589d8ka.htm   iXBRL 8-K/A 25572
2 EX-99.1 d342589dex991.htm EX-99.1 67571
  Complete submission text file 0001193125-23-066791.txt   231438

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA prme-20230309.xsd EX-101.SCH 2868
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE prme-20230309_lab.xml EX-101.LAB 18685
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE prme-20230309_pre.xml EX-101.PRE 11704
7 EXTRACTED XBRL INSTANCE DOCUMENT d342589d8ka_htm.xml XML 4374
Mailing Address 21 ERIE ST. CAMBRIDGE MA 02139
Business Address 21 ERIE ST. CAMBRIDGE MA 02139 617-465-0013
Prime Medicine, Inc. (Filer) CIK: 0001894562 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-41536 | Film No.: 23721667
SIC: 2836 Biological Products, (No Diagnostic Substances)